These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Huncharek M; Kupelnick B Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895 [TBL] [Abstract][Full Text] [Related]
4. Risk-adapted use of intravesical immunotherapy. Braasch MR; Böhle A; O'Donnell MA BJU Int; 2008 Nov; 102(9 Pt B):1254-64. PubMed ID: 19035890 [No Abstract] [Full Text] [Related]
5. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer. Evans CP Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082 [No Abstract] [Full Text] [Related]
6. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
7. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done? Soloway MS; Arianayagam M Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403 [No Abstract] [Full Text] [Related]
8. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors. Boccon-Gibod L Prog Clin Biol Res; 1992; 378():55-7. PubMed ID: 1301586 [No Abstract] [Full Text] [Related]
9. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. Lamm DL; Riggs DR; Traynelis CL; Nseyo UO J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962 [TBL] [Abstract][Full Text] [Related]
10. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents]. Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135 [TBL] [Abstract][Full Text] [Related]
11. BCG in the management of superficial bladder cancer. Guinan P; Richardson C; Hanna M; Rubenstein M Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002 [TBL] [Abstract][Full Text] [Related]
12. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related]
13. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]
14. When does superficial bladder cancer resist intravesical therapy? Vögeli T; Ackermann R Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531 [No Abstract] [Full Text] [Related]
15. Is intravesical chemotherapy for superficial bladder cancer still justified? Okeke AA; Probert JL; Gillatt DA; Schwaibold H BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195 [No Abstract] [Full Text] [Related]
16. Intravesical and systemic chemotherapy of murine bladder cancer. Soloway MS Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041 [No Abstract] [Full Text] [Related]
17. Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop. Sylvester R Eur Urol; 2007 Jun; 51(6):1748-50. PubMed ID: 17374436 [No Abstract] [Full Text] [Related]
18. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer. van der Meijden AP Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591 [No Abstract] [Full Text] [Related]